RheumaView · Chapter 16 · Patient guide
Preparing for an r-axSpA follow-up visit: how to bring the information that actually changes decisions
Bring a short account of what changed, the medicines you actually received and the questions that matter most. The Visit Planner supports that conversation; it is not a disease-activity score, a diagnostic test or a message to a clinic.
In this chapter
- You do not need to tell the entire story again
- Start with what improved
- Then identify what did not improve
- Check your understanding 1
- Describe patterns—not just pain numbers
- Morning stiffness: estimate it simply
- Night pain: say what actually happens
- Function: what can you actually do?
- Check your understanding 2
- If you use ASDAS or BASDAI, bring the trend—not a stack of scores
- Do not chase a questionnaire number
- Medication: bring what actually happened
- Access problems belong in the medical history
- If you skipped medication because of an infection, say exactly what happened
- What about side effects?
- Eye, skin and bowel disease should be part of every relevant follow-up
- Check your understanding 3
- Peripheral disease deserves its own line
- Safety events can matter even if the medication worked perfectly
- New trauma belongs near the top of the list—not the bottom
- Labs: bring the result that answers a question
- Know whether CRP is useful in your disease
- Imaging: bring the actual study information when it matters
- Do not assume every follow-up needs new imaging
- Bring outside records selectively
- The three-question rule
- Check your understanding 4
- State the agenda near the beginning
- What if everything is stable?
- What if the treatment is working extremely well?
- What if you think the treatment is failing?
- A one-minute treatment timeline
- Tell the clinician what matters most to you now
- A useful visit structure
- Use the companion Visit Planner
- Leave with a next step
- The key message
- Where to go next
- Selected evidence sources
Before filling in a worksheet: urgent symptoms need assessment first.
A new painful red eye, light sensitivity or blurred vision needs ophthalmological assessment the same day. These symptoms do not all need to occur together. If you cannot reach an eye service, use an urgent-care or emergency route that can arrange assessment. Do not wait for the next routine rheumatology appointment. [S10]
New neck or back pain after a fall or injury deserves particular concern when the spine is fused or markedly stiff. Seek emergency assessment for a suspected spinal injury. Avoid unnecessary movement; do not let someone forcibly straighten a fixed deformity. Tell the emergency team about your usual spinal position. [S02, S12]
With new or worsening back or leg pain, a new change in bladder emptying or sensation, bowel control, sexual function, or feeling around the genitals/bottom needs emergency assessment now. Do not wait for all symptoms or for complete incontinence. New substantial weakness or difficulty walking also needs urgent assessment. [S11]
Severe infection or another rapidly developing illness also needs prompt medical care. Read the urgent-symptom guide.
You do not need to tell the entire story again
At a routine follow-up, the goal is usually not to repeat every detail from the beginning of your illness.
If the clinician already knows your history, focus first on the interval since the last assessment. For a new clinician, bring a concise diagnostic and treatment history as well.
What matters most is:
What changed since the last meaningful assessment?
A good opening summary might be:
“Morning stiffness and night pain improved substantially after treatment, but I still have focal pain after standing. I missed two doses because of infection, had one episode of uveitis, and I am functioning better at work.”
That contains much more useful information than:
“My pain is still a six.”
Start with what improved
Patients often spend most of the visit describing what still hurts.
That makes sense—but it can hide evidence that a treatment is working.
Before your visit, ask:
Since the last visit, what is better?
Examples:
- less morning stiffness;
- less nighttime pain;
- fewer awakenings;
- easier walking;
- better ability to exercise;
- less fatigue;
- better work function;
- less need for NSAIDs;
- fewer peripheral-joint symptoms;
- less enthesis pain;
- better psoriasis;
- no further uveitis;
- improved bowel disease;
- better CRP or ASDAS.
Improvement helps the clinician understand which part of the treatment is effective.
Then identify what did not improve
Now ask:
What remains a problem?
Try to be specific.
Instead of:
“My back still hurts.”
consider:
“The inflammatory morning stiffness is much better, but I still develop focal low-back pain after standing for 30 minutes.”
Or:
“Everything improved for three months, but over the last six weeks the same nighttime pain and two-hour morning stiffness have returned.”
These descriptions lead to different decisions.
Check your understanding 1
Which statement gives the clinician more useful information?
A
“My treatment isn’t working because I still have pain.”
B
“My morning stiffness went from two hours to 20 minutes, CRP normalized and I sleep better, but activity-related pain remains in one area of my lower back.”
Answer: B.
The second description suggests meaningful inflammatory improvement while also identifying a residual problem that may require a different explanation.
Describe patterns—not just pain numbers
A pain score can be useful.
But the pattern usually adds more information.
Before the visit, consider:
When is pain worst?
- first thing in the morning?
- during the second half of the night?
- after prolonged rest?
- after prolonged standing or activity?
- at the end of the day?
What makes it better?
- moving?
- resting?
- changing position?
- NSAIDs?
- heat?
Is this familiar or new?
Does it feel like your usual inflammatory pain?
Or is it:
- more focal;
- more mechanical;
- burning or electric;
- widespread;
- related to trauma;
- or distinctly different?
These details help separate active inflammation from other pain mechanisms.
Morning stiffness: estimate it simply
You do not need a stopwatch.
A reasonable estimate is enough.
Think about the usual pattern over the recent period:
0–15 minutes
15–30 minutes
30–60 minutes
1–2 hours
more than 2 hours
Also note whether it has:
- improved;
- worsened;
- or remained stable.
The change is often more informative than the exact number.
These rough categories are for discussion. They are not the official ASDAS input questions and must not be converted into an ASDAS calculation. If your clinician supplies a standardized questionnaire, use its exact questions and time frame. [S05]
Night pain: say what actually happens
Instead of checking only:
“Night pain: yes.”
try to describe it.
For example:
- I wake once because of back pain.
- I wake several times.
- Pain improves when I get up and walk.
- I cannot find a comfortable position.
- I am awake for another reason and then notice pain.
- Night pain has disappeared since treatment started.
This can help distinguish inflammatory symptoms from sleep or mechanical problems.
Function: what can you actually do?
Disease activity and function are not the same thing.
A useful follow-up should include what has changed in real life.
Consider:
- walking;
- stairs;
- driving;
- sitting;
- standing;
- bending;
- dressing;
- putting on shoes;
- exercise;
- work;
- household tasks;
- childcare;
- sleep;
- travel.
Try to identify one or two concrete changes.
For example:
“I can now walk two miles again.”
or:
“I can no longer turn my neck enough to check the blind spot while driving.”
Those statements are more actionable than:
“Function is worse.”
Check your understanding 2
Which functional update is more useful?
A
“My back is bad.”
B
“I can exercise again, but neck rotation has decreased enough that driving is becoming difficult.”
Answer: B.
It tells the clinician both what improved and what now needs attention.
If you use ASDAS or BASDAI, bring the trend—not a stack of scores
Some clinics use standardized disease-activity measures such as:
- ASDAS;
- BASDAI.
ASAS–EULAR favors ASDAS, which combines symptoms and an inflammatory marker. The 2026 ACR summary supports regular use of ASDAS or BASDAI. Follow the instrument your clinic uses and bring dated results. [S01, S02, S05]
You do not need to calculate it every day.
If your clinic uses ASDAS, useful information is:
- previous score;
- current score;
- whether the change was meaningful.
A decrease in ASDAS of at least 1.1 points represents a clinically important improvement.
But the score should still be interpreted together with the clinical picture.
A decrease of at least 2.0 is a major ASDAS improvement. The measurement chapter explains thresholds, CRP units and limitations. The Visit Planner calculates neither score. [S05]
Do not chase a questionnaire number
Suppose:
- pain remains high;
- sleep is poor;
- fibromyalgia is present;
- CRP is normal;
- objective inflammatory findings are limited.
A high symptom score may still be important.
But it does not automatically mean:
“More immunosuppression is required.”
Bring the score.
Also bring the story that explains the score.
Medication: bring what actually happened
This is one of the most important sections of the visit.
Do not simply write:
“Taking medication as prescribed.”
Instead ask:
What medication am I actually using?
Include:
- targeted therapy;
- NSAIDs;
- steroids if any;
- other pain medications;
- relevant supplements or nonprescription medications.
Was it taken on schedule?
If not, why?
Examples:
- infection;
- antibiotics;
- surgery;
- insurance delay;
- pharmacy delay;
- travel;
- forgot;
- adverse effect;
- uncertain when to restart.
These details are clinically useful.
They are not a confession.
Access problems belong in the medical history
If a treatment is repeatedly delayed because of:
- authorization;
- pharmacy supply;
- insurance;
- copay problems;
tell the clinician.
A medication cannot be judged fairly if the patient has been unable to receive it consistently.
Sometimes the treatment decision is:
fix access
rather than:
change mechanism.
If you skipped medication because of an infection, say exactly what happened
Useful details include:
- what infection occurred;
- whether antibiotics were required;
- whether there was fever;
- whether you were hospitalized;
- how long treatment was held;
- when it was restarted.
Do not rely on memory if several interruptions occurred.
A short timeline is enough.
What about side effects?
Bring side effects that matter.
Examples:
- recurrent infection;
- injection reaction;
- rash;
- gastrointestinal symptoms;
- persistent headache;
- oral thrush;
- laboratory abnormality;
- another symptom that repeatedly follows treatment.
Try to include:
when it happened in relation to the medication
rather than just listing symptoms.
Timing often helps assess causality.
Eye, skin and bowel disease should be part of every relevant follow-up
These manifestations can change treatment decisions even when the spine is doing well.
EYES
Since the last visit:
- any painful red eye?
- photophobia?
- blurred vision?
- diagnosed uveitis?
- ophthalmology visit?
- how many episodes?
A confirmed episode of uveitis is particularly useful information.
SKIN / NAILS
Any:
- new psoriasis;
- worsening psoriasis;
- scalp involvement;
- nail changes;
- palms/soles;
- genital involvement?
Photographs can sometimes help document a rash that disappears before the appointment.
But a photograph does not substitute for dermatologic diagnosis when the eruption is unclear.
BOWEL
Any:
- persistent diarrhea;
- blood in stool;
- urgency;
- abdominal pain;
- unexplained weight loss;
- known Crohn disease or ulcerative colitis becoming more active?
These symptoms may affect treatment choice.
Check your understanding 3
The back is doing very well.
Since the previous visit the patient has had three episodes of confirmed anterior uveitis.
Is “spine controlled” enough information?
No.
The eye disease may materially change the systemic treatment discussion.
Peripheral disease deserves its own line
Do not forget:
- swollen joints;
- heel pain;
- Achilles symptoms;
- plantar fascia pain;
- chest-wall pain;
- dactylitis if present.
But try to distinguish:
new swelling/inflammation
from:
chronic mechanical pain.
A photograph of a clearly swollen joint during an episode may sometimes be useful if the swelling resolves before the visit.
Safety events can matter even if the medication worked perfectly
Tell the clinician about important events such as:
- serious infection;
- hospitalization;
- surgery;
- blood clot;
- new cardiovascular event;
- new cancer diagnosis;
- significant liver abnormality;
- major neurologic diagnosis;
- pregnancy or pregnancy planning;
- new inflammatory bowel disease;
- vaccination questions;
- or other major changes in medical history.
A medication can be effective and still require reconsideration because the risk context has changed.
New trauma belongs near the top of the list—not the bottom
New neck or back pain after a fall or injury deserves particular concern when the spine is fused or markedly stiff. Seek emergency assessment for a suspected spinal injury. Avoid unnecessary movement; do not let someone forcibly straighten a fixed deformity. Tell the emergency team about your usual spinal position. [S02, S12]
Do not save current concerning symptoms for a routine appointment. Once an injury has been assessed, record the date, findings, treatment and any residual change in function so the rheumatology team can incorporate it into follow-up.
Labs: bring the result that answers a question
Useful laboratory information may include:
- CRP;
- ESR;
- CBC;
- liver tests;
- kidney function;
- medication-specific monitoring;
- other tests related to a new problem.
But more tests are not automatically more useful.
A follow-up visit should not become a contest to collect the largest laboratory panel.
The question is:
Which result helps us understand disease activity, treatment safety, or another current problem?
Copy the date, value and units. For example, CRP in mg/L and mg/dL are different units. Write “not available” rather than guessing; bring the report if possible. The worksheet does not interpret the value or change treatment.
Know whether CRP is useful in your disease
Some people have a CRP that rises reliably when axSpA becomes active.
Others have persistently normal CRP even during clinically active disease.
That distinction is worth knowing.
Ask:
“Has CRP historically tracked my disease?”
If the answer is no, a normal CRP should not be given more weight than it deserves.
Imaging: bring the actual study information when it matters
If imaging was performed outside the treating system, useful information includes:
- date;
- body region;
- modality;
- report;
- and, when possible, access to the actual images.
The report alone may not answer every question.
Prior images can be especially valuable for comparison.
Do not assume every follow-up needs new imaging
Routine follow-up does not require:
- a new X-ray;
- a new MRI;
simply because several months have passed.
Imaging should answer a specific question.
Examples:
- Is current inflammation uncertain?
- Did trauma cause structural injury?
- Is another pain generator suspected?
- Is there a meaningful structural comparison that would affect management?
More imaging is not automatically more careful medicine.
Bring outside records selectively
A 300-page packet is often less useful than five relevant items.
For a focused r-axSpA follow-up, priority may include:
- recent imaging;
- important recent labs;
- ophthalmology documentation of uveitis;
- gastroenterology findings;
- hospitalization records;
- major medication changes.
The goal is not to prove that you have had extensive medical care.
It is to give the clinician the evidence relevant to today’s decisions.
The three-question rule
Choose up to three priorities and state them early. This is a communication aid, not a limit on reporting important symptoms or safety concerns.
For example:
- What is the main cause of the activity I still find difficult?
- Does recurrent uveitis change the treatment discussion?
- What will tell us that the next step is working, and when should I contact the team?
Use additional notes for other questions. Urgent issues take precedence over the routine agenda.
Check your understanding 4
Which visit strategy is more effective?
A
Bring a list of 27 loosely related questions and begin with the least important.
B
Identify the three decisions that matter most and state them early.
Answer: B.
Other questions can still be addressed when time allows.
Priority improves communication.
State the agenda near the beginning
A useful opening can be:
“There are three things I especially want to address today: whether the treatment is still controlling inflammation, my recurrent eye inflammation, and whether my new hip pain needs separate evaluation.”
This helps both patient and clinician organize the visit.
It is not demanding.
It is efficient.
What if everything is stable?
A stable visit still matters.
Useful information may simply be:
- symptoms remain controlled;
- function is stable;
- no new uveitis/psoriasis/IBD;
- no significant infection;
- medication is tolerated;
- no access problems;
- no major new medical condition.
Then the decision may correctly be:
continue the current plan.
Not every appointment should produce a medication change.
Stability is an outcome.
What if the treatment is working extremely well?
Mention that clearly.
It matters for future decision-making.
Examples:
“I am 80% better.”
“I no longer wake at night.”
“I am exercising again.”
“My morning stiffness is now 10 minutes.”
“I have not needed NSAIDs for two months.”
If the clinician hears only about residual symptoms, the magnitude of treatment benefit can be underestimated.
What if you think the treatment is failing?
Bring a simple timeline.
BEFORE TREATMENT
What were the main inflammatory symptoms?
AFTER STARTING
Did anything improve?
When?
BEST POINT
How good did control become?
NOW
What has returned or changed?
This helps distinguish:
- primary nonresponse;
- partial response;
- secondary loss of response;
- and a new non-inflammatory problem.
A one-minute treatment timeline
For example:
January: started biologic. February–April: major improvement in stiffness and night pain. May: insurance delayed one dose by three weeks. June: symptoms increased, then improved after regular dosing resumed. August–September: morning stiffness again increased despite regular treatment; CRP now elevated.
That is much easier to interpret than:
“It worked, then didn’t work, then maybe worked again.”
Tell the clinician what matters most to you now
Priorities change.
At one visit, the main goal may be:
“Stop waking at night.”
Later:
“I want to return to running.”
Later:
“My neck mobility is affecting driving.”
Treatment should respond to current priorities when medically possible.
The clinician cannot know the priority unless you say it.
A useful visit structure
A well-prepared follow-up can follow this order:
1. MAIN CHANGE
Better, worse, or mixed?
2. INFLAMMATORY PATTERN
Morning stiffness, night pain, familiar inflammatory symptoms.
3. FUNCTION
What can you do now compared with before?
4. TREATMENT
Actual doses, interruptions, benefit and adverse effects.
5. OTHER SpA MANIFESTATIONS
Eye, skin, bowel, peripheral joints, entheses.
6. SAFETY / NEW EVENTS
Infection, trauma, hospitalization, major new diagnosis.
7. OBJECTIVE DATA
Relevant CRP, labs, imaging.
8. THREE QUESTIONS
What decisions do you need from this visit?
That is enough for an excellent clinical conversation.
Use the companion Visit Planner
The worksheet organizes the information needed to decide whether to continue the plan, investigate persistent symptoms, address another manifestation, arrange rehabilitation or discuss a medicine change.
Open the Visit Planner. Use the main fields for the review period, improvement, current difficulty, stiffness/night symptoms, one functional change, actual medication use, important events, dated tests and three questions. Optional notes hold extra detail.
The worksheet’s application code does not send answers or save them in browser storage. It asks for no name, date of birth, account or uploaded records. Use Print to make your own copy and Clear after use, especially on a shared device. Browser features and copies you save or print can retain information; this is not a guarantee about the whole device.
The blank A4 worksheet and blank US Letter worksheet each use one page. Long typed answers can continue over additional pages when printed from the HTML worksheet rather than being cut off.
This independent educational website is not a clinic portal. Give completed notes to your treating team through its normal channels.
Leave with a next step
Before the visit ends, confirm what happens next: tests, a referral, any exact medication instructions, when follow-up is expected and how to contact the team sooner. Ask for clarification if a change is unclear. Keep the clinician’s instructions with your medication list; your worksheet is not a new prescription.
The key message
A productive r-axSpA follow-up does not require perfect records.
It requires the right information.
Bring:
what improved
what remains difficult
whether the inflammatory pattern changed
what you can and cannot do
what medication you actually received
important eye, skin or bowel events
major safety events
relevant labs or imaging
and:
the three questions you most need answered.
The purpose is not to impress the clinician with how much information you collected.
It is to make the treatment decision clearer.
The best visit summary is not the longest one.
It is the one that helps answer: what is happening now, why, and what should we do next?
Where to go next
- Measuring activity
- When treatment seems not to work
- Choosing targeted therapy
- Eye, skin and bowel disease
- New pain needing faster assessment
- Remission and treatment reduction
- Back to the patient guide
Selected evidence sources
S01. American College of Rheumatology / Spondylitis Association of America / SPARTAN. 2026 axial spondyloarthritis guideline summary. Posted June 24, 2026. Source.
S02. Ramiro S, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19–34. doi:10.1136/ard-2022-223296. Source.
S03. Zhao SS, et al. The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs. Rheumatology. 2025. doi:10.1093/rheumatology/keaf089. Executive summary: doi:10.1093/rheumatology/keaf090. Source.
S05. Assessment of SpondyloArthritis international Society. ASDAS calculator and calculation guidance. Source.
S10. NICE. Spondyloarthritis in over 16s: diagnosis and management. NG65. Source.
S11. Somerset NHS Foundation Trust. Cauda equina syndrome: spinal surgery service patient guidance. Source.
S12. NICE. Spinal injury: assessment and initial management. NG41. Source.
Sources checked: October 1, 2026. Examples and checkpoints are fictional educational scenarios.
Educational information only. This article supports discussion with your clinicians and does not give an individual diagnosis or medication prescription.